
Opinion|Videos|July 10, 2024
Targeting Pathways Downstream of Dystrophin: Vamorolone and Givinostat in Duchenne Muscular Dystrophy
Author(s)Emma Ciafaloni, MD
Emma Ciafaloni, MD, discusses therapies for Duchenne muscular dystrophy that target pathways downstream of dystrophin, focusing on vamorolone and givinostat.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Discuss the efficacy and safety of vamorolone, a corticosteroid, which was FDA approved in 2023 for patients with Duchenne muscular dystrophy (DMD) aged 2 years and older.
- Where does givinostat, a pan-histone deacetylase inhibitor, that was FDA approved in 2024, fit in the treatment landscape of DMD?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Grants Fast Track Designation to T-Cell Agent CK0803 for ALS
2
5-Year Data Support Safety of MRI-Guided AAV2-GDNF Gene Therapy in Advanced Parkinson Disease
3
AHA/ASA Issue New Guideline for Adult Stroke Rehabilitation and Recovery
4
Top 5 Spinal Muscular Atrophy Headlines of 2026: What Neurologists Should Know
5



















